Literature DB >> 15332115

Robust infectivity and replication of Delta-24 adenovirus induce cell death in human medulloblastoma.

Robert Stolarek1, Candelaria Gomez-Manzano, Hong Jiang, Gary Suttle, Michael G Lemoine, Juan Fueyo.   

Abstract

The diverse advanced treatment modalities currently available to children with medulloblastoma, including surgery and radiotherapy, are associated with deleterious side effects and often with an unfavorable prognosis. A mutant adenovirus, Delta-24, which has a 24-base pair deletion in the Rb-binding region of the E1A gene, demonstrates selective replication and oncolysis in various malignant phenotypes. Here we report the ability of Delta-24 to kill medulloblastoma cells. Flow cytometric analyses of cell receptors demonstrated expression of the coxsackie adenovirus receptor and RGD-related integrins in the assessed medulloblastoma cell lines. Infectivity assays using a replication-deficient adenovirus to transduce the green fluorescence protein gene showed that the Delta-24 adenovirus infects 99% of Daoy and 46% of D283 Med medulloblastoma cells at a multiplicity of infection (MOI) of 50. Within 4 days after infecting medulloblastoma cells with Delta-24, a noticeable cytopathic effect was produced. Delta-24 induced a total cytopathic effect in Daoy and D283 Med medulloblastoma cells after 6 and 8 days of infection, respectively. In the infected population of cells, cell death correlated with the accumulation of cells in the S phase. At 5 days post-infection with 2.5 MOIs of Delta-24 adenovirus, the percentage of Daoy medulloblastoma cells in the S phase increased to 71.9+/-5.5%, compared with control values of 20.5+/-1.4%. The release of viral progeny was quantified as being increased by two orders of magnitude, indicating efficient replication of Delta-24 in medulloblastoma cells. This is the first report of the ability of oncolytic adenoviruses to infect and kill medulloblastoma cells, the findings of which suggest the potential efficacy of Delta-24 as a therapy for human medulloblastoma tumors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15332115     DOI: 10.1038/sj.cgt.7700731

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  8 in total

1.  E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models.

Authors:  S C Cheong; Y Wang; J-H Meng; R Hill; K Sweeney; D Kirn; N R Lemoine; G Halldén
Journal:  Cancer Gene Ther       Date:  2007-11-23       Impact factor: 5.987

2.  Detection of drug-induced cellular changes using confocal Raman spectroscopy on patterned single-cell biosensors.

Authors:  Ryan Buckmaster; Fareid Asphahani; Myo Thein; Jian Xu; Miqin Zhang
Journal:  Analyst       Date:  2009-04-30       Impact factor: 4.616

3.  Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells.

Authors:  J L Dembinski; E L Spaeth; J Fueyo; C Gomez-Manzano; M Studeny; M Andreeff; F C Marini
Journal:  Cancer Gene Ther       Date:  2009-10-30       Impact factor: 5.987

4.  Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin.

Authors:  Xue Qing Lun; Hongyuan Zhou; Tommy Alain; Beichen Sun; Limei Wang; John W Barrett; Marianne M Stanford; Grant McFadden; John Bell; Donna L Senger; Peter A Forsyth
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

5.  Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo.

Authors:  Stephan Leitner; Katrina Sweeney; Daniel Oberg; Derek Davies; Enrique Miranda; Nick R Lemoine; Gunnel Halldén
Journal:  Clin Cancer Res       Date:  2009-02-17       Impact factor: 12.531

6.  Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers.

Authors:  Daniel Oberg; Eva Yanover; Virginie Adam; Katrina Sweeney; Celina Costas; Nick R Lemoine; Gunnel Halldén
Journal:  Clin Cancer Res       Date:  2010-01-12       Impact factor: 12.531

Review 7.  Oncolytic Viruses as Therapeutic Tools for Pediatric Brain Tumors.

Authors:  Maider Varela-Guruceaga; Sonia Tejada-Solís; Marc García-Moure; Juan Fueyo; Candelaria Gomez-Manzano; Ana Patiño-García; Marta M Alonso
Journal:  Cancers (Basel)       Date:  2018-07-09       Impact factor: 6.639

8.  From Immunosuppression to Immunomodulation - Turning Cold Tumours into Hot.

Authors:  Mariangela Garofalo; Katarzyna Wanda Pancer; Magdalena Wieczorek; Monika Staniszewska; Stefano Salmaso; Paolo Caliceti; Lukasz Kuryk
Journal:  J Cancer       Date:  2022-07-04       Impact factor: 4.478

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.